INVO Bioscience’s mission is to increase access to care and expand fertility treatment and patient care across the globe. For many couples struggling with infertility, access to treatment is often not possible. Financial challenges, limited availability of specialized medical care, religious, social or cultural roadblocks can prevent these hopeful parents from realizing their dream to have a baby.
INVOcell is the first Intravaginal Culture (IVC) system granted FDA clearance in the United States, providing millions of infertile couples across the country access to this revolutionary infertility treatment. This novel device and procedure provides a more natural, safe, effective and economical fertility treatment. The INVOcell device and INVO Procedure will provide couples the opportunity to have an additional option other than the thirty-year-old traditional treatments, Intrauterine Insemination (IUI) and In Vitro Fertilization (IVF).
A Revolutionary in vivo incubation
The patented INVOcell device is used for the incubation of eggs and sperm during fertilization and early embryo development. Unlike conventional infertility treatments such as IVF where the eggs and sperm develop into embryos in a laboratory incubator, the INVOcell utilizes the women’s vagina as an incubator to support a more natural fertilization and embryo development environment. This novel device promotes in vivo conception and early embryo development. In clinical studies, the INVO Procedure produced equivalent efficacy and pregnancy rates to traditional IVF treatments.
During an INVO Procedure, the patient undergoes a mild ovarian stimulation cycle. Once the eggs are retrieved and sperm is collected, they are placed into the INVOcell device. The INVOcell device is immediately positioned in the upper vaginal cavity for incubation, where natural fertilization and early development of the embryos take place.